£515.00

It has never been this cheap. We have no record of a lower price.

£515 today · cheaper than every other day in the last 3 months

The 2023-2028 Outlook for HPV and CMV Therapeutics in India

View at Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 37 days · 37 data points (no recent data)

Historical
Generating forecast…
£515.00 £489.25 £499.55 £509.85 £520.15 £530.45 £540.75 22 August 2026 31 August 2026 09 September 2026 18 September 2026 27 September 2026
View at Amazon ↗

Price data last checked 54 day(s) ago - refreshing...

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

Price distribution over 37 days • 1 price levels

Days at Price
37 days 0 9 19 28 37 £515 Days at Price

Price Analysis

Most common price: £515 (37 days, 100.0%)

Price range: £515 - £515

Price levels: 1 different prices over 37 days

Description

This study covers the latent demand outlook for HPV and CMV therapeutics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for HPV and CMV therapeutics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of HPV and CMV therapeutics as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AbbVie, Actavis Generics (Actavis, PLC), Allergan, Bausch Health, Biotest, Clinigen Group, Fougera Pharmaceuticals, Fresenius Kabi, GlaxoSmithKline, Lee’s Pharmaceutical Holdings, Merck & Company, Perrigo Company, Roche Holdings, and Valeant Pharmaceuticals International. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).

Product Specifications

Format
paperback
Domain
Amazon UK
Release Date
14 September 2022
Listed Since
28 September 2022

Similar Products You Might Like

The 2023-2028 Outlook for HPV Vaccines in India
82% match

The 2023-2028 Outlook for HPV Vaccines in India

£515.00 16 Oct 2026
The 2023-2028 Outlook for Dermatophytic Onychomycosis Therapeutics in India
80% match

The 2023-2028 Outlook for Dermatophytic Onychomycosis Therapeutics in India

£515.00 06 Sep 2026
The 2023-2028 Outlook for Oligonucleotide Therapeutics in India
80% match

The 2023-2028 Outlook for Oligonucleotide Therapeutics in India

£515.00 21 Oct 2026
The 2023-2028 Outlook for Dermatophytic Onychomycosis Systemic Therapies in India
80% match

The 2023-2028 Outlook for Dermatophytic Onychomycosis Systemic Therapies in India

£515.00 06 Sep 2026
The 2023-2028 Outlook for Chemotherapy-Induced Nausea and Vomiting Drugs in India
80% match

The 2023-2028 Outlook for Chemotherapy-Induced Nausea and Vomiting Drugs in India

£515.00 06 Sep 2026
The 2023-2028 Outlook for Hormone-Drug Breast Cancer Therapeutics in India
80% match

The 2023-2028 Outlook for Hormone-Drug Breast Cancer Therapeutics in India

£515.00 06 Sep 2026
The 2023-2028 Outlook for Topical Atrophic Scar Treatment Products in India
79% match

The 2023-2028 Outlook for Topical Atrophic Scar Treatment Products in India

£515.00 06 Sep 2026
The 2023-2028 Outlook for Pap Smear Tests for Cervical Cancer Diagnostic Testing in India
79% match

The 2023-2028 Outlook for Pap Smear Tests for Cervical Cancer Diagnostic Testing in India

£515.00 29 Oct 2026
The 2023-2028 Outlook for Testosterone Replacement Therapies in India
79% match

The 2023-2028 Outlook for Testosterone Replacement Therapies in India

£515.00 06 Sep 2026
The 2023-2028 Outlook for Geriatric Medicines in India
79% match

The 2023-2028 Outlook for Geriatric Medicines in India

£515.00 16 Oct 2026
The 2023-2028 Outlook for Onychomycosis (Tinea Unguium) Drugs in India
79% match

The 2023-2028 Outlook for Onychomycosis (Tinea Unguium) Drugs in India

£515.00 06 Sep 2026
The 2023-2028 Outlook for Dermatophytic Onychomycosis Therapeutics in the United States
79% match

The 2023-2028 Outlook for Dermatophytic Onychomycosis Therapeutics in the United States

£520.00 06 Sep 2026
The 2023-2028 Outlook for Corneal Ulcer Treatments in India
79% match

The 2023-2028 Outlook for Corneal Ulcer Treatments in India

£515.00 26 Oct 2026
The 2023-2028 Outlook for Life Science Products in India
79% match

The 2023-2028 Outlook for Life Science Products in India

£515.00 06 Sep 2026
The 2023-2028 Outlook for Dermatophytic Onychomycosis Treatments in India
79% match

The 2023-2028 Outlook for Dermatophytic Onychomycosis Treatments in India

£515.00 06 Sep 2026
The 2023-2028 Outlook for Peripheral Vascular Devices in India
79% match

The 2023-2028 Outlook for Peripheral Vascular Devices in India

£515.00 21 Oct 2026
The 2023-2028 Outlook for Topical Pigmentation Disorders Treatment Drugs in the United States
79% match

The 2023-2028 Outlook for Topical Pigmentation Disorders Treatment Drugs in the United States

£520.00 06 Sep 2026
The 2026-2031 World Outlook for Vaginitis Therapeutics
79% match

The 2026-2031 World Outlook for Vaginitis Therapeutics

£885.00 28 Sep 2026
The 2023-2028 Outlook for Oligonucleotide Therapeutics in the United States
79% match

The 2023-2028 Outlook for Oligonucleotide Therapeutics in the United States

£520.00 13 Nov 2026
The 2023-2028 Outlook for Oral Tinea Pedis (Athlete's Foot) Treatments in India
79% match

The 2023-2028 Outlook for Oral Tinea Pedis (Athlete's Foot) Treatments in India

£515.00 26 Oct 2026
The 2023-2028 Outlook for Persistent Corneal Epithelial Defects Treatments in India
78% match

The 2023-2028 Outlook for Persistent Corneal Epithelial Defects Treatments in India

£515.00 29 Oct 2026
The 2023-2028 Outlook for Homeopathic Products in India
78% match

The 2023-2028 Outlook for Homeopathic Products in India

£515.00 06 Sep 2026
The 2023-2028 Outlook for Pap Smear Tests for Cervical Cancer Diagnostic Testing in the United States
78% match

The 2023-2028 Outlook for Pap Smear Tests for Cervical Cancer Diagnostic Testing in the United States

£520.00 27 Oct 2026
The 2023-2028 Outlook for Personal Video Recorders (PVRs) in India
78% match

The 2023-2028 Outlook for Personal Video Recorders (PVRs) in India

£515.00 06 Sep 2026